The partnership comes off the back of the success of the 100,000 Genomes Project in December 2018. More: Genomics England, Illumina join forces on whole genome sequencing Source: News
read moreNovartis’ inclisiran will be studied in UK patients as part of a large-scale NHS clinical trial, which is expected to start later this year. More: Novartis, NHS strike ‘innovative’ cardiovascular deal Source: News
read moreThe group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma. More: Zytiga, Ajovy among latest SMC decisions Source: News
read moreSAN FRANCISCO—Novartis’ history of scandals—and apologies for those scandals—might make anyone skeptical of CEO Vas Narasimhan’s pledge to make trust a top priority. But now the company is taking the promise a step further. Into Narasimhan’s own pocket, in fact. More: JPM: With
read moreLast year, Bristol-Myers Squibb stole the show at the J.P. Morgan Healthcare Conference with its $74 billion deal agreement for Celgene. But one year later, with the deal just recently closed, company CEO Giovanni Caforio says he feels “even better
read moreIt’s January, which means the annual J.P. Morgan Healthcare Conference in San Francisco is back on, and drugmakers of all shapes and sizes are doing their best to woo investors. What we’re hearing so far? Lots of deal PRs, sales projections
read more© 1994 - 2026 B.M. Pharmaceuticals